Breakthrough Technologies That De-Risk Tomorrow’s Biologics
Beyond standard development pipelines, Elise Biopharma invests in high-impact platforms that solve the toughest manufacturability and performance challenges. Our Advanced Services & Innovation hub integrates synthetic biology, novel analytics, and cutting-edge bioprocessing to unlock possibilities traditional CDMOs can’t reach. Explore each capability below, then click through for the full technical brief.
Precision Fermentation
Next-Gen Microbial Factories for Food, Pharma, and Industrial Biotech
Elise’s precision-fermentation suite couples CRISPR-edited microbes with AI-driven fed-batch control to express animal-free proteins, specialty enzymes, and sustainable food ingredients at scale. Real-time Raman spectroscopy and digital twin modeling maintain carbon-to-nitrogen ratios and oxygen transfer windows within ±2 % of design specs, yielding ≥25 g L⁻¹ soluble product with batch-to-batch CV <5 %. Downstream, continuous TFF and multimodal chromatography deliver log-scale impurity clearance while recovering >85 % activity—ideal for regulatory-sensitive food and pharma markets.
Glycoengineering & Glycoform Optimization
Fine-Tuning Glycans for Potency, Half-Life, and Reduced Immunogenicity
Glycan structure dictates effector function, PK profile, and safety. Our CHO- and HEK-based glycoengineering platform enables fucose knock-outs, bisecting GlcNAc control, sialylation enhancement, and α-Gal/Neu5Gc elimination via targeted host-cell glycosyltransferase editing. Elise combines CRISPR design with glycan-flux modeling and high-throughput LC-MS glyco-fingerprinting to hit predefined glycoform envelopes with >90 % reproducibility. Applications span ADCC-boosted mAbs, liver-targeted fusion proteins, and “biobetter” versions of legacy biologics.
Analytical & Quality Control Services
Regulatory-Grade Characterization, Delivered In-House
Our 8 000 ft² analytical center of excellence provides CMC-ready method development and validation under cGMP / ISO 13485. Key assets include:
- High-Resolution Mass Spec (Orbitrap & Q-TOF) for intact mass, peptide mapping, and PTMs
- Multi-angle Light Scattering SEC-MALS for aggregate/monomer quantitation down to 0.1 %
- SPR/BLI Kinetics & Cell-Based Potency for binding and functional release tests
- qPCR/ddPCR & Residual Host-Cell Protein/DNA Panels pre-qualified for FDA filings
- ICH Stability Chambers (–80 °C to 50 °C, 10–90 % RH) networked to 21 CFR Part 11 LIMS
By embedding these assays throughout development, Elise shortens method-transfer timelines and supplies turnkey data packages for IND, IMPD, BLA, or IVDR submissions.
Specialty & Emerging Modalities
Innovation Sandbox for Bispecifics, Nanobodies, Cell-Free Synthesis, and Beyond
When your molecule defies standard playbooks, our Specialty team steps in. We design and scale bispecific T-cell engagers (BiTEs), albumin-fusion cytokines, VHH nanobodies, scaffold proteins, and cell-free-expressed enzymes using bespoke vector architectures and hybrid purification trains. Rapid prototyping in micro-bioreactors or cell-free lysates delivers mg-scale material in days, while dedicated CHO & E. coli suites push the same construct to GMP kilograms without tech-transfer risk. Integrated bioinformatics predicts aggregation hotspots, pI shifts, and developability flags—avoiding late-stage surprises.
Why These Capabilities Matter
| Challenge | Traditional CDMO Gap | Elise Advanced Solution |
|---|---|---|
| Precise glycoform control for enhanced ADCC | Limited to host’s natural glycosylation | CRISPR-based glycosyltransferase editing + LC-MS mapping |
| High-titer expression of non-canonical proteins | Toxicity to host, low yield | Precision fermentation with dynamic feed algorithms |
| Rapid analytics for IND timelines | Outsourced assays, slow turn | On-site HR-MS, SPR/BLI, cell potency labs |
| Scaling novel modalities (BiTEs, nanobodies) | Lack of format-specific know-how | Dedicated Specialty Modalities team with hybrid workflows |
Engage With Elise Innovation
- Discovery Sprint – 4-week feasibility: expression or glyco-editing proof-of-concept + analytics report.
- Design-Space Mapping – DoE-driven parameter screen, digital-twin simulations, and glycoform envelope definition.
- Pilot & Tech Transfer – 20 L to 200 L runs, purification scale-down, and analytic method qualification.
- GMP Launch – Full QbD process characterization, PPQ, and regulatory dossier support.
Ready to de-risk the cutting edge? Contact us today!